Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

12 Essential Softwares in Pharma Industry in 2026 for GMP Quality Manufacturing and Compliance

Explore the essential software systems that support GMP quality, manufacturing, laboratory control, and compliance. This guide explains how QMS, MES, LIMS, and ERP platforms manage critical data, reduce integration risks, and strengthen inspection readiness across pharmaceutical operations.
  • Blog, Computerized System Validation
Pharmaceutical manufacturing software connecting quality, laboratory, production, and compliance workflows in a modern GMP facility.

Pharma Data Analyst Jobs in 2026: Skills, Salary, Career Paths, and GMP Expectations

Explore how pharmaceutical data analyst roles combine SQL, Power BI, clinical data management, and data integrity in pharma. Learn where analysts work, which skills employers value, how salaries vary, and why regulated data knowledge matters for career growth.
  • Blog, Computerized System Validation
Professional reviewing pharmaceutical data analytics dashboards in a modern pharma environment with quality and compliance indicators.

CAR-T Growth Multiplies Patient-Specific Runs; Every Quality-System Link Must Scale

Commercial CAR-T growth requires thousands of patient-specific production runs rather than larger batches. PharmaVoice reported on September 1 that patient material, production, quality testing and release, logistics, and treatment schedules must move together. Consequently, expansion can magnify quality-system variability and
  • News
CAR-T Growth Multiplies Patient-Specific Runs; Every Quality-System Link Must Scale

Pharma Document Management System in 2026: GMP Document Control and Inspection Readiness

Learn how pharmaceutical teams can strengthen document control, manage electronic records, support data integrity, and prepare for inspections. This guide explains key system controls, audit expectations, and practical checks for a more reliable GMP documentation process.
  • Blog, Computerized System Validation
Pharmaceutical quality professional using an electronic system for controlled records, audit trail review, and data integrity oversight

Novocure Devices Stayed Secure; 1,400+ U.S. Patient Records Put Digital Quality Under Scrutiny

Novocure reported that unauthorized access to certain information systems in mid-August exposed records linked to more than 1,400 U.S. patients. The company confirmed that its medical treatment devices were not accessed and all systems remain operational. Nevertheless, the incident highlights
  • News
Novocure Devices Stayed Secure; 1,400+ U.S. Patient Records Put Digital Quality Under Scrutiny

Pharma Data Science in 2026: Applications, AI, and GMP Compliance

Explore how data science in pharma supports AI, machine learning, manufacturing analytics, and GMP decisions. Learn where data quality, validation, human oversight, and inspection readiness matter most across the pharmaceutical lifecycle, from development to post-market safety.
  • Blog, Computerized System Validation
Pharma 4.0 environment with pharmaceutical analysts reviewing data dashboards beside a modern manufacturing line.

FDA and Duke Advance QMIN; Quantitative Medicine Gains Regulatory Momentum

The FDA and Duke-Margolis Institute for Health Policy convened a virtual summit on September 1 to help shape the Quantitative Medicine Innovation Network (QMIN). The planned cross-sector network would connect regulators, industry, academia, healthcare providers and patient groups to advance
  • News
FDA and Duke Advance QMIN; Quantitative Medicine Gains Regulatory Momentum

3 Deaths Pause 8 Novartis CAR-T Trials; Safety Review Now Expands

Novartis paused eight clinical trials of an experimental CAR-T therapy for autoimmune and neurological disorders in late August after 3 patient deaths linked to a severe immune response. The Swiss drugmaker is reviewing the safety events with independent safety boards
  • News
3 Deaths Pause 8 Novartis CAR-T Trials; Safety Review Now Expands